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Measures of Right Heart Strain Before and After CDT
Pre-
CDT
Mean
SD Post-
CDT
Mean
SD Difference
Mean
SD P
Value
RVSP 53.1 15.1 38.5 10.2 14.5 12.6 <0.001
RV/LV 1.48 0.32 1.17 0.26 0.32 2.16 <0.001
Qanadli
Index
49 18 34 13 15.4 10.1 <0.001
JVIR ▪ Scientific Sessions Tuesday ▪ S99Materials: The retrospective IRB approved study investigates the
treatment group of 25 patients who underwent catheter based
therapy consisting of single, or combination mechanical and
chemical lytic therapy. The controls were patients with PE matched
for similar severity of disease RV/LV ratio and other risk other
factors. Controls were given medical management including sys-
temic anticoagulation only. All available pre- and postprocedural
cardiac imaging including CTA, and Echo were used to assess RV
strain. Strain was measured using am established comparison of
RV to LV diameters.
Results: Over a one year, 25+patients at a single institution un-
derwent catheter based therapy. Two devices had been used, either
alone or in combination; Penumbra’s Indigo, and BTG’s Ekos were
used. A roughly equal total dose of lytics (TPA) was given in both
groups averaging 28 mg administered either single dose or 22hr
infusion. Average preprocedure diagnosis was 1 day, and post
procedure follow-up 1.8 days. RV/LV ratios between the two
groups suggested a significant improvement right ventricular strain
as measured by a change in RV/LV ratio.
Conclusions: Catheter based therapy showed improvement in
outcome measure vs medical management alone comparing right
heart strain. A combination of catheter based tools including me-
chanical aspiration of clot, and directed lytics may be used in in-
termediate and high-risk PE patients safely. If widely available,
catheter based therapy stands also to change the practices of
Interventional physician’s approach analogous to other cardiac
emergencies such as STEMI creating the expectation expectation to
provide emergent or semi-emergent responses.TUESDAY:Scientific
Sessions4:03 PM Abstract No. 228
Ultrasound-assisted catheter-directed
thrombolysis for submassive pulmonary
embolism: efficacy in relief of right heart strain
J. Manov1, F. Contreras2, M. Langston3, M. Doshi2,
P. Mohan4; 1University of Miami School of Medicine,
Miami, FL; 2University of Miami, Miami, FL; 3University
of Miami Miller School of Medicine, Miami, FL;
4Universiy of Miami Miller School of Medicine, Miami,
FL
Purpose: To determine the outcomes, safety profile, and efficacy
of ultrasound-assisted catheter-directed thrombolysis for pulmo-
nary embolism with right heart strain.
Materials: The charts of 30 consecutive patients who underwent
CDT as treatment for pulmonary embolism were reviewed. Risk
factors for bleeding were noted. Indicators of right heart strain on
computed tomography and echocardiogram, as well as degree of
pulmonary vascular obstruction, were recorded before and after
CDT. Thirty-day mortality and occurrence of bleeding events were
recorded.
Results: Right ventricular systolic pressure decreased from an
average of 53.1 mm Hg to 38.5 mm Hg (p ¼ <0.001) and average
Qanadli index of pulmonary vascular obstruction decreased from
49 to 34 (p ¼ <0.001) after CDT. The average ratio of RV/LV
diameter decreased from 1.48 to 1.17 (p ¼ <0.001) The number of
patients with RV hypokinesis decreased significantly (p ¼ 0.016)
from 19 (95% of those with available data) to 12 (60%). The
number of patients with RV dilation decreased significantly (p ¼
0.031) from 19 (95% of those with available data) to 13 (65%).Nine (30%) patients had three or more minor contraindications to
thrombolysis and fourteen (47%) had had major surgery in the
month prior to CDT. No patients experienced major or moderate
bleeding attributed to CDT.
Conclusions: In our experience CDT proved effective in the
rapid alleviation of right heart strain with minimal bleeding risk.
Right heart strain is associated with increased mortality and long-
term morbidity in pulmonary embolism and CDT may allow for a
safe means of improving outcomes in submassive pulmonary
embolism. We found CDT to be a safe alternative to systemic
thrombolysis in patients with risk factors for bleeding such as prior
surgery.4:12 PM Abstract No. 229
The thromboaspiration with INDIGO system
reduces the time and dose of fibrinolysis and
improves the results in massive pulmonary
embolism in comparison with catheter
fragmentation (previous cohort study)
J. Guirola Ortiz1, C. Serrano Casorran2,
D. Jimenez Castro3, M. Sanchez Ballestin2,
A. Figueredo Cacacho4, W. Kuo5, M. De Gregorio6;
1Lozano Blesa University Hospital, Zaragoza, Zaragoza;
2GITMI. Minimally invasive techniques research
group., Zaragoza, Zaragoza; 3Hospital Ramon y Cajal,
Madrid (Espa~na), Madrid, Madrid; 4Hospital
Universitario Miguel Servet. Zaragoza. Spain,
Zaragoza, Zaragoza; 5Stanford University Medical
Center, Stanford, CA; 6Universidad de Zaragoza. Spain,
Zaragoza, Spain
Purpose: Determine if thromboaspiration with indigo system
improves short- and medium-term outcomes compared with
interventional treatment of choice for pulmonary embolism (PE)
(mechanical thrombolysis + catheter-directed thrombolytic
therapy).
Materials: From Apr-2016 to Aug-2017, 43 patients diagnosed
massive PE and a comparative with previous study of 111 patients
with massive PE. In the first cohort all patients were treated with
thromboaspiration + catheter-directed thrombolytic therapy (TAs)
and the other cohort were treated with conventionally according to
our protocol: thrombolysis + catheter fragmentation (MFT). There
were no significant differences in age, sex and the angiographic
pulmonary index (Miller index). Pulmonary pressures after fibri-
nolysis and one month later were compared. The total dose and the
total time of fibrinolysis were also compared in both groups.
Results: Postoperative mean pulmonary arterial pressure (PAPm)
was 34.06 ± 5.81 mm Hg TAs and 39.46 ± 6.39 mm Hg MFT,
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the 24hours and after 1- month angiographic control. There were
significant differences in the total dose administered of urokinase
(UK) (1.38 ± 0.25 IU of UK TAs MFT vs 2.82 ± 0.89 million IU
of UK MFT) and the total time of UK perfusion (13.05 ± 1.70
hours TAs vs. 21.69 ± 11.92 hours MFT). four patients (9.3%) died
in the follow-up in the cohort TAs with only 1 (2.3%) related to PE
vs. 7 patients (6.3%) with only 4 (3.6%) related to PE or compli-
cations of endovascular treatment MFT.
Conclusions: Thromboaspiration improves the results of con-
ventional mechanical fragmentation and catheter-directed throm-
bolytic therapy, decreasing the time and total dosage of fibrinolysis
and also decreasing PAP more rapidly.4:21 PM Abstract No. 230
Length of hospital stay in submassive pulmonary
embolism patients who underwent ultrasound-
assisted catheter-directed thrombolysis
Z. Zhang1, R. Rao1, A. Vinzons2, D. Ruiz1, S. Pham1,
K. Omonuwa2, J. Arampulikan2; 1Harlem Hospital
Center, New York, NY; 2Lincoln Medical Center, Bronx,
NY
Purpose: Emerging evidence suggests ultrasound-assisted cath-
eter-directed thrombolysis (UACDT) decreases right ventricular
dilation, reduces pulmonary hypertension, and minimizes risk of
intracranial hemorrhage in patients with acute submassive pulmo-
nary embolism (PE). It is important to identify clinical factors that
may affect these patients’ hospital stays to facilitate patient care.
We aimed to evaluate factors associated with the length of intensive
care unit (ICU) and hospital stays in acute submassive PE patients
who underwent UACDT.
Materials: Clinical data of patients who underwent UACDT
(EkoSonic™ Endovascular System, Bothell, Washington) for
submassive PE between 1/2016 and 7/2017 was reviewed. Tissue-
plasminogen activator was administered at 1 mg/h for 12 hours and
titrated per Fibrinogen levels. Linear regression was used to eval-
uate the association with log-transformation of non-parametric
length of stay data.
Results: Among the 31 patients enrolled, 17 were male. The
mean (±SD) age was 54 ± 17 years. The mean (±SD) Pulmonary
Embolism Severity Index and RV/LV ratio were 92 ± 38 and 1.34
± 0.36, respectively. The median troponin and BNP levels were
0.117 and 251, respectively. The median length of ICU and
hospital stays were 45 hours and 5 days, respectively. There were
no complications. After adjusting for all factors in the regression
model, the RV/LV ratio was significantly associated with longer
ICU (b-coefficient ¼ 0.87, 95%CI 0.29,1.45, p ¼ 0.005) and
hospital stays (b-coefficient ¼ 1.27, 95%CI 0.52,2.01, p ¼
0.002).
Conclusions: UACDT is safe for submassive (intermediate-high
risk) PE patients with the median length of ICU and hospital
stays of 45 hours and 5 days, respectively. Increased RV/LV ratio
is associated with longer ICU and hospital stays. Our data sug-
gests that RV dilation is an important prognostic factor of these
patients.Scientific Session 24
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The pivotal multicenter trial of ultrasound-
guided percutaneous arteriovenous fistulae
creation for hemodialysis access
J. Hull1, W. Jennings2, R. Cooper3, U. Waheed4,
M. Schaefer5, R. Narayan6; 1Richmond Vascular
Center, North Chesterfield, VA; 2University of
Oklahoma, Tulsa, OK; 3Southwest Vascular Center,
Tempe, AZ; 4Southwest Kidney Institute, Phoenix,
AZ; 5SAKDC, San Antonio, TX; 6San Antonio Kidney
Disease Center, San Antonio, TX
Purpose: To evaluate the safety and efficacy of the percuta-
neous arteriovenous fistulae (pAVF) created with a thermal
resistance anastomosis device (TRAD).
Materials: One hundred seven patients were enrolled in a
prospective single arm trial at 5 sites. Patients underwent ul-
trasound-guided anastomosis creation between the proximal
radial artery and perforating vein with the Ellipsys® Vascular
Access System followed by separate maturation procedures.
The primary endpoints were brachial artery flow volume  500
mL/min and target vein diameter  4 mm in > 49% of patients,
and absence of device related complications at 90 days.
Results: Arteriovenous fistulae with fused anastomoses were
created in 95% (102/107) patients. Maturation procedures
included anastomotic balloon dilation in 72% (77/107), brachial
vein embolization in 32% (34/107), cubital vein ligation in 31%
(33/107), and surgical transposition in 26% (28/107). The pri-
mary flow and diameter endpoints were achieved in 86.0% (92/
107) of patients exceeding the performance goal of 49% (p <
0.0001). There were no major adverse events attributed to the
device. Cumulative patency was 91.6%, 89.3%, 86.7% at 90,
180, and 360 days, respectively. The target dialysis vein was the
cephalic, basilic, and brachial veins in 74% (73/99), 24% (24/
99), 2% (2/99), respectively. 2-needle dialysis was achieved in
88% (71/81) of patients on hemodialysis at a mean of 114.3 ±
66.2 days. Functional patency was 98.4%, 98.4%, and 92.3% at
90, 180, and 360 days, respectively.
Conclusions: The Ellipsys® Vascular Access System met the
primary safety, and efficacy endpoint goals in the United States
pivotal trial.
